Thus, the apoptotic rate was more than 2-fold higher in pancreatic NETs and more than 6-fold higher in pituitary NETs of pasireotide-treated Men1+/− mice. This evidence concerns the gene MEN1 and pancreatic neuroendocrine tumor.